OTOTOXICITY IN MULTIDRUG-RESISTANT TUBERCULOSIS: A SCOPING REVIEW OF THE INDONESIAN STUDIES
pdf

Keywords

MDR-TB
Ototoxicity
Second-line injectable

How to Cite

Putra, O., N.H., A., Hidayat, F., & Sagitha, I. (2022). OTOTOXICITY IN MULTIDRUG-RESISTANT TUBERCULOSIS: A SCOPING REVIEW OF THE INDONESIAN STUDIES. Journal of Pharmaceutical And Sciences, 5(1), 62-73. https://doi.org/10.36490/journal-jps.com.v5i1.71
Abstract viewed = 0 times
pdf downloaded = 0 times

Abstract

A wide variation in ototoxicity or hearing loss due to injectable anti-tubercular drugs in patients with multidrug-resistant tuberculosis (MDR-TB) has been reported globally and in Indonesia. This scoping review assesses the ototoxicity of second-line injectable anti-tubercular drugs in Indonesian patients with MDR-TB. This review was conducted under the recommended PRISMA extension for scoping review (PRISMA-ScR). The Google Scholar and PubMed database were used to search the articles on MDR-TB in the Indonesian population. Seven studies were identified based on the inclusion criteria reporting kanamycin and capreomycin in the management of MDR-TB. Ototoxicity was observed in 39.3% (116/295) MDR-TB patients. Ototoxicity was observed in kanamycin, 38.7% (105/271 patients); capreomycin, 36,8% (7/19 patients); and kanamycin plus capreomycin, 80% (4/5 patients).  Only one study reported risk factors ototoxicity in MDR-TB patients. Ototoxicity was significantly associated with older age and the length of kanamycin therapy correlates with hearing loss. This review identified a high prevalence of ototoxicity in Indonesian patients with MDR-TB treated with second-line injectable drugs. Efforts were urgently needed to develop guidelines for monitoring ototoxicity, improving pharmacist and clinician awareness, and educating patients or caregivers to report hearing loss symptoms as a sign of ototoxicity.

 

Keywords: MDR-TB; Ototoxicity, Second-line injectable

 

 

https://doi.org/10.36490/journal-jps.com.v5i1.71
pdf

References

Adetola BE (2019). Alarming levels of ototoxicity among multidrug resistant tuberculosis patients on intensive phase of treatment at specialist treatment centers in South western, Nigeria. J. Public Health Epidemiol. 11(7):145-151

Alemu A, Bitew ZW, Worku T, Gamtesa DF, Alebel A. (2018). Predictors of mortality in patients with drug-resistant tuberculosis: A systematic review and meta-analysis. PLoS ONE. 16(6):e0253848

American Speech-Language-Hearing Association (ASHA) Ad Hoc Committee. Audiologic management of individuals receiving cochleotoxic drug therapy. 1994. Avaialable from https://www. asha.org/policy/GL1994-00003.htm

Brahmono A, Purnami N, Surarso B. (2021). Cochlear dysfunction after kanamycin injection in multidrug resistant tuberculosis patients. Folia Medica Indones. 56(3):216-222.

British Society of Audiology. Pure Tone Air and Bone Conduction Threshold Audiometry with and without Masking; 2011. Available from: http://www.thebsa.org.uk/wp-content/uploads/2011/ 04/Pure-Tone-Audiometry-1.pdf

de Vasconcelos KA, Frota SMMC, Ruffino-Netto A, Kritski AL. (2017). The importance of audiometric monitoring in patients with multidrug-resistant tuberculosis. Rev Soc Bras Med Trop. 50(5):646-651

Dillard LK, Martinez RX, Perez LL, Fullerton AM, Chadha S, McMahon CM.(2021). Prevalance of aminoglycosiede-induced hearing loss in drug-resistant tuberculosis patients: A systematic review. Journal of Infection. 83:27-36

Ernest JP, Sarathy J, Wang N, Kaya F, Zimmerman MD, Strydom N, et al. (2021). Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis. Antimicrob Agents Chemother. 65(10):e0050621

Fitriya L, Artanti KD. (2020). Treatment outcomes of multidrug resistant tuberculosis patients in east java from 2014 to 2017. Jurnal Berkala Epidemiologi. 8(2):141-148

Ghafari N, Court R, Chirehwa MT, Wiesner L, Maartens G, Gumbo T, et al. (2020). hearing loss in patients with multi-drug resistant tuberculosis. Int J Audiol. 59(3):219-221.

Heysell SK, Ahmed S, Rahman MT. (2018). Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh. Eur Respir J. 51:1701778

Hong H, Dooley KE, Starbird LE, Francis HW, Farley JE. (2019). Adverse outcome pathway for aminoglycosides ototoxicity in drug-resistant tuberculosis treatment. Acrh Toxicol. 93(5):1385-1399

Hong H, Budhathoki C, Farley JE. (2018) Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection. Int J Tuberc Lung Dis. 22(6):667-674

Ibrahim E, Baess AI, Al Messery MA. (2017). Pattern of prevalence, risk factors and treatment outcomes among Egyptian patients with multidrug resistant tuberculosis. Egypt J Chest Dis Tuberc. 66(3):405–11.

Irwan A, Memy YD, Ahmad Z, Bahar E, Septiany C. (2017). Correlation between the length of kanamycin therapy and hearing threshold shift in Multidrug Resistant Tuberculosis (MDR-TB patients. J Res Med Dent Sci. 5(6):113–8.

Khairani AP, Santoso P, Setiawati EP. (2017). Role of risk factors in the incidence of multidrug-resistant tuberculosis. International Journal of Integrated Health Science. 5(2):57-63

Kranzer K, Elamin WF, Cox H, Seddon JA, Ford N, Drobniewski F. (2015). A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: Implications for the treatment of multidrug-resistant TB. Thorax.70(11):1070–7.

Mantefardo B, Sisay G. Case report: Kanamycin ototoxicity and MDR-TB treatment regimen. (2021). Int Med Case Reports J.14:815-817

Ministry of Health of Indonesia Republic. Programmatic management of drug resistance tuberculosis 2011-2014. Jakarta 2016. Available from: https://www.who.int/docs/default-source/searo/indonesia/non-who-publications/programmatic-management-of-drug-resistance-tb-in-indonesia-2011-2014-bahasa.pdf?sfvrsn=aa2e3df1_2

Mustikaningtyas E, Purnami E. (2013). Hearing disorders in multidrug-resistant tuberculosis patients at the outpatients unit, pulmonary department, Dr. Soetomo hospital Surabaya. Folia Medica Indones. 49(4):263-267

Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. (2019). Treatment of drug-resistant tuberculosis an official ATS/CDC/ERS/IDSA clinical practice guideline. American Journal of Respiratory and Critical Care Medicine. 200(10):93–142.

Poluan FH. (2020). Comparison of the effectiveness of alpha-tocopherol and ginkgo biloba extract on the prevention of ototoxic kanamycin in the treatment of multiple drug-resistant tuberculosis. European Journal of Molecular & Clinical Medicine. 7(3):4736–51.

Rachna D, Shabnam S. (2017). Sensorineural hearing loss in patients with multidrug-resistant tuberculosis: Case studies. Acta Oto-Laryngologica Case Reports. 2(1):96-102

Rahmawati I, Isbaniah F, Agustin H, Sarikencana RE. (2019). The prevalence of ototoxicity in drug resistance tuberculosis patients and the associated factors at Persahabatan General Central Hospital. J Respir Indo. 39(3):180-95.

Rakhmawati L, Agustian RA, Wijana. (2015). Probability of kanamycin ototoxicity in multidrug resistant tuberculosis patients during first month treatment. Maj Kedokt Bandung. 47(4):224–30.

Ratnawati M, Reviono, Putranto W, Yusup SS. (2017). Effects of risk factors on the onset of Kanamycin’s adverse events in drug resistant tuberculosis. Maj Kedokt Bandung. 50(2):86–92.

Reviono R, Widayanto W, Harsini H, Aphridasari J, Sutanto YS. (2013). Streptomycin and incidence of hearing loss in multidrug resistant tuberculosis patients in Dr. Moewardi Hospital. J Respir Indo. 33(3):167-72.

Rumende CM. (2018). Risk Factors for Multidrug-resistant Tuberculosis. Acta Med Indones. 50(1):1–2.

Sabur NF, Brar MS, Wu L, Brode SK. (2021). Low-dose amikacin in the treatment of multidrug-resistant tuberculosis (MDR-TB). BMC Infec Dis. 21:254

Sarin R, Behera D, Khanna A, Singh V, Narang P, Deepak TS. (2019). Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies. Indian J Tuberc. 66(2):279–87.

Shibeshi W, Sheth AN, Admasu A, Berha AB, Negash Z, Yimer G. (2019). Nephrotoxicity and ototoxic symptoms of injectable second-line anti-Tubercular drugs among patients treated for MDR-TB in Ethiopia: A retrospective cohort study. BMC Pharmacol Toxicol. 20(1):1–10.

Soeroto AY, Pratiwi C, Santoso P, Lestari BW. (2021). Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study. PLoS ONE.:e0246284

Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. (2018). PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 169(7):467–73.

Wahyudin W, Indrasworo D, Wahyudiono AD. (2019). Association between kanamycin with ototoxicity in multidrug resistant tuberculosis patients. Oto Rhino Laryngol Indones. 48(2):121-128

Wangchuk P, Adhikari TR, Nima G, Dendup P. (2021) Audiological monitoring of patients undergoing multidrug resistant tuberculosis treatment at Jigme Dorji Wangchuk National referral hospital and Gidakom hospital, Bhutan. J Clin Tuberc and Other Myc Dis. 23:100229

Wang SF, Zhou Y, Pang Y, Zheng HW, Zhao YL. (2016). Prevalence and risk factors of primary drug-resistant tuberculosis in China. Biomed Environ Sci. 29(2):91–8.

Wang Y, Chen H, Huang Z, McNeil EB, Lu X, Chongsuvivatwong V. (2019). Drug non-adherence and reasons among multidrug-resistant tuberculosis patients in Guizhou, China: A cross-sectional study. Patients Preferences and Adherence. 13:1641-1653

World Health Organization. (2016). WHO treatment guidelines for drug- resistant tuberculosis 2016 Update [internet]. Available from: https://www.who.int/publications/i/item/9789241549639

Yulianti Y, Mahdiani S. (2015). Hearing disorders in multidrug resistant tuberculosis. Oto Rhino Laryngol Indones. 45(2):83-89.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.